Cambridge Nucleomics closes oversubscribed £550 k pre-seed round

Cambridge Nucleomics has successfully closed an oversubscribed £550 k pre-seed round led by Cambridge Angels with participation from Cambridge Technology Capital.

In a strong vote of confidence toward Nucleomics' founding team and revolutionary modular soluble nanoarray (MSN) technology platform, this capital injection will directly fund the advancement of our proprietary assay for fast, highly multiplexed nucleic acid biomarker detection.

Our immediate clinical focus is the development of a rapid, one-hour automated point-of-care test for sepsis. By enabling pathogen identification (ID) within the critical first hour of patient admission and soon genetic antimicrobial resistance (AMR) profiling directly from blood without culture, this proof-of-concept will demonstrate the unprecedented speed and multiplexing capabilities of our enzyme-free technology. 

We are proud to welcome John Yeomans, commercialisation veteran and former chair of Cambridge Angels, and Cantabio Director Max Zhu, PhD MBA to our board to advance our commercial strategy. Their combined expertise will be instrumental in navigating the transition from early-stage R&D towards a clinical-stage diagnostic platform.